Search Results

ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, today announced that it has acquired Respicardia, Inc., a provider of novel implantable neurostimulators for the treatment of moderate to severe Central Sleep Apnea (CSA). CSA is a serious condition that is often associated with heart failure, coronary artery disease, and certain cardiac arrhythmias

Respicardia, Inc., the manufacturer of the only FDA-approved active implantable system for the treatment of central sleep apnea, announced that Highmark Blue Cross Blue Shield and its affiliates will provide coverage for the Company’s remedē® System therapy, effective immediately.

All of Respicardia’s existing major investors helped to complete the financing round.

The first case coincides with the naming of seasoned medical device executive, Peter Sommerness, as CEO of Respicardia and leader of the remede System U.S. launch.

Respicardia has announced 5-year results from the remedē System Post Approval Study, assessing the safety and efficacy of transvenous phrenic nerve stimulation for the treatment of moderate to severe central sleep apnea (CSA).

Respicardia Also Initiates 500-Patient Prospective, Global, Single-Arm Longitudinal Study

ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that the United States Food and Drug Administration (FDA) has approved the remedē System for conditional use with magnetic resonance imaging (MRI).